{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:46:06Z","timestamp":1790397966897,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.humimm.2018.12.006","type":"journal-article","created":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T20:13:55Z","timestamp":1544904835000},"page":"184-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cytokine-targeted therapy for the management of solid organ transplant recipients"],"prefix":"10.1016","volume":"80","author":[{"given":"Amanda","family":"Szczepanik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo J.","family":"Iasella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"McDyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Ensor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.humimm.2018.12.006_b0005","first-page":"11","article-title":"Annual data report: introduction","volume":"2017","author":"OPTN\/SRTR","year":"2015","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.humimm.2018.12.006_b0010","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drug for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.humimm.2018.12.006_b0015","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.humimm.2018.12.006_b0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1600-6143.2007.02057.x","article-title":"A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients","volume":"8","author":"Vincenti","year":"2008","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.humimm.2018.12.006_b0025","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.humimm.2018.12.006_b0030","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/ajt.13710","article-title":"Calcineurin inhibitor minimization, conversion, withdrawal, and avoidance strategies in renal transplantation: a systematic review and meta-analysis","volume":"16","author":"Sawinski","year":"2016","journal-title":"Am. J. Transplant."},{"issue":"4","key":"10.1016\/j.humimm.2018.12.006_b0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00054725-199911000-00009","article-title":"Th1\/Th2 cells","volume":"5","author":"Romagnani","year":"1999","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.humimm.2018.12.006_b0040","first-page":"123","article-title":"New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors","volume":"99","author":"Dong","year":"2017","journal-title":"Cutis"},{"key":"10.1016\/j.humimm.2018.12.006_b0045","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2174\/1389203717666160902130001","article-title":"Cytokine expression profile as predictive surrogate biomarkers for clinical events in the field of solid organ transplantation","volume":"18","author":"Boix","year":"2017","journal-title":"Curr. Portein Pept. Sci."},{"issue":"4","key":"10.1016\/j.humimm.2018.12.006_b0050","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.4049\/jimmunol.159.4.1658","article-title":"Characterization of IL-12 receptor beta1 chain (IL-12Rbeta1)-deficient mice: IL-12Rbeta1 is an essential component of the functional mouse IL-12 receptor","volume":"159","author":"Wu","year":"1997","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.humimm.2018.12.006_b0055","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.4049\/jimmunol.165.11.6221","article-title":"IL-12 receptor beta 2 (IL-12R beta 2)-deficient mice are defective in IL-12-mediated signaling despite the presence of high affinity IL-12 binding sites","volume":"165","author":"Wu","year":"2000","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.humimm.2018.12.006_b0060","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nri954","article-title":"The lineage decisions of helper T cells","volume":"2","author":"Murphy","year":"2002","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.humimm.2018.12.006_b0065","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nrd1441","article-title":"A new modality for immunosuppression: targeting the JAK\/STAT pathway","volume":"3","author":"O\u2019Shea","year":"2004","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.humimm.2018.12.006_b0070","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ncomms2260","article-title":"T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements","volume":"3","author":"Kanhere","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.humimm.2018.12.006_b0075","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/925135","article-title":"CD4+T cells: differentiation and functions","volume":"2012","author":"Luckheeram","year":"2012","journal-title":"Clin. Dev. Immunol."},{"issue":"11","key":"10.1016\/j.humimm.2018.12.006_b0080","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/ni1128","article-title":"Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses","volume":"5","author":"Zhu","year":"2004","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.humimm.2018.12.006_b0085","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/MOT.0b013e32833b9bfb","article-title":"The impact of TH17 cells on transplant rejection and the induction of tolerance","volume":"15","author":"Heidt","year":"2010","journal-title":"Curr. Opin. Organ Transplant."},{"issue":"3","key":"10.1016\/j.humimm.2018.12.006_b0090","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/j.gastro.2012.05.049","article-title":"IL-17 signaling in inflammatory cells, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis","volume":"143","author":"Meng","year":"2012","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.humimm.2018.12.006_b0095","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nri2580","article-title":"New insights into the regulation of T cells by \u0263c family cytokines","volume":"9","author":"Rochman","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.humimm.2018.12.006_b0100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.clinbiochem.2015.07.026","article-title":"Chemokines and transplant outcome","volume":"49","author":"Crescioli","year":"2016","journal-title":"Clin. Biochem."},{"issue":"6","key":"10.1016\/j.humimm.2018.12.006_b0105","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.immuni.2015.12.003","article-title":"Th17 cell pathway in human immunity: lessons from genetics and therapeutics interventions","volume":"43","author":"Patel","year":"2015","journal-title":"Immunity"},{"issue":"7446","key":"10.1016\/j.humimm.2018.12.006_b0110","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature11981","article-title":"Dynamic regulatory network controlling Th17 cell differentiation","volume":"496","author":"Yosef","year":"2013","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.humimm.2018.12.006_b0115","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.4049\/jimmunol.179.8.5462","article-title":"Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F","volume":"179","author":"Kuestner","year":"2007","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.humimm.2018.12.006_b0120","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni.1813","article-title":"Structural basis of receptor sharing by interleukin 17 cytokines","volume":"10","author":"Ely","year":"2009","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.humimm.2018.12.006_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/1744666X.2016.1112739","article-title":"Interleukin 17-A inhibition in the treatment of psoriasis","volume":"12","author":"Yiu","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"7318","key":"10.1016\/j.humimm.2018.12.006_b0130","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature09447","article-title":"Generation of pathogenic T(H)17 cells in the absence of TGF-\u03b2 signaling","volume":"467","author":"Ghoreschi","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.humimm.2018.12.006_b0135","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.194.4.519","article-title":"Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense","volume":"194","author":"Ye","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.humimm.2018.12.006_b0140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2008.11.009","article-title":"Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses","volume":"30","author":"Ishigame","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.humimm.2018.12.006_b0145","doi-asserted-by":"crossref","unstructured":"E.M. Moran, R. Mullan, J. McCormick, M. Connolly, O. Sullivan, O. FitzGerald, et al., Human rheumatoid arthritis tissue production of IL-17A drive matrix and cartilage degradation: synergy with tumor necrosis factor-\u03b1, Oncostatin M and response to biologic therapies, Arthritis Res. Ther., 11(4), doi:10.1186\/ar2772, R113.","DOI":"10.1186\/ar2772"},{"key":"10.1016\/j.humimm.2018.12.006_b0150","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","article-title":"Interleukin-1 and IL-23 induce innate IL-17 production from \u0263\u03b4 T cells, amplifying Th17 responses and autoimmunity","volume":"31","author":"Sutton","year":"2009","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.humimm.2018.12.006_b0155","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1084\/jem.20061308","article-title":"Interleukin (IL)-22 and IL-17 are co-expressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides","volume":"203","author":"Liang","year":"2006","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.humimm.2018.12.006_b0160","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4049\/jimmunol.162.1.577","article-title":"Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors","volume":"162","author":"Antonysamy","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2018.12.006_b0165","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1681\/ASN.V981526","article-title":"Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection","volume":"9","author":"Van Kooten","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.humimm.2018.12.006_b0170","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00007890-200107270-00035","article-title":"Interleukin-17 antagonism inhibits acute but not chronic vascular rejection","volume":"72","author":"Tang","year":"2001","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.humimm.2018.12.006_b0175","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0022","article-title":"The biology and medical implications of interleukin-6","volume":"2","author":"Tanaka","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.humimm.2018.12.006_b0180","first-page":"4","article-title":"Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells","author":"Ma","year":"2015","journal-title":"F1000 Res."},{"issue":"4","key":"10.1016\/j.humimm.2018.12.006_b0185","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1189\/jlb.0412214","article-title":"Regulation of inflammation by interleukin-4: a review of \u201calternatives\u201d","volume":"92","author":"Luzina","year":"2012","journal-title":"J. Leukoc Biol."},{"key":"10.1016\/j.humimm.2018.12.006_b0190","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.transproceed.2015.12.059","article-title":"Association interleukin-4 and interleukin-4 receptor gene polymorphism and acute rejection and graft dysfunction after kidney transplantation","volume":"48","author":"Lee","year":"2016","journal-title":"Transplant. Proc."},{"issue":"4","key":"10.1016\/j.humimm.2018.12.006_b0195","first-page":"333","article-title":"An updated on interleukin-4 and its receptor","volume":"8","author":"Chomarat","year":"1997","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.humimm.2018.12.006_b0200","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/157488812799859856","article-title":"Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD) \u2013 are serum\/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (allo-HCT)?","volume":"7","author":"Toubai","year":"2012","journal-title":"Curr. Stem Cell Res. Ther."},{"issue":"4","key":"10.1016\/j.humimm.2018.12.006_b0205","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2009-01-197178","article-title":"Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease","volume":"114","author":"Chen","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.humimm.2018.12.006_b0210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-10-1198","article-title":"Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation","volume":"17","author":"Tawara","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"1 Pt 2","key":"10.1016\/j.humimm.2018.12.006_b0215","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1067\/mai.2000.106774","article-title":"Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation","volume":"106","author":"Nakamura","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"issue":"Suppl 2","key":"10.1016\/j.humimm.2018.12.006_b0220","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/annrheumdis-2012-202371","article-title":"Effect of IL-17A blockade with secukinumab in autoimmune diseases","volume":"72","author":"Patel","year":"2013","journal-title":"Ann. Rheum Dis."},{"key":"10.1016\/j.humimm.2018.12.006_b0225","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/jcph.876","article-title":"Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis","volume":"57","author":"Bruin","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.humimm.2018.12.006_b0230","unstructured":"Cosentyx\u00ae [package insert]. East Hanover, New Jersey; Novartis Pharmaceuticals Corporation, 2017."},{"key":"10.1016\/j.humimm.2018.12.006_b0235","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinuman inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.humimm.2018.12.006_b0240","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2567.2008.03017.x","article-title":"Interleukin-17 in host defence against bacterial, mycobacterial, and fungal pathogens","volume":"126","author":"Curtis","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.humimm.2018.12.006_b0245","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1086\/422329","article-title":"Requirement of IL-17A for systemic anti-Candida albicans host defense in mice","volume":"190","author":"Huang","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.humimm.2018.12.006_b0250","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.humimm.2018.12.006_b0255","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/jdv.13990","article-title":"Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two phase III randomized studies","volume":"31","author":"Gottlieb","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.humimm.2018.12.006_b0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14712598.2017.1363884","article-title":"Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders","volume":"9","author":"Balato","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"issue":"6","key":"10.1016\/j.humimm.2018.12.006_b0265","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/bjd.15723","article-title":"Infections from 7 clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2018.12.006_b0270","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1182\/blood.V98.12.3309","article-title":"Increased granulopoiesis through interleukin-17 and granulocyte colony-stimulating factor in leukocyte adhesion molecule-deficient mice","volume":"98","author":"Forlow","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2018.12.006_b0275","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","article-title":"Dupilumab: first global approval","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs."},{"key":"10.1016\/j.humimm.2018.12.006_b0280","unstructured":"Dupixent\u00ae [package insert]. Tarrytown, NY, Regeneron Pharmaceuticals, 2017."},{"key":"10.1016\/j.humimm.2018.12.006_b0285","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3389\/fimmu.2017.00667","article-title":"Interleukin-6 in allogeneic stem cell transplantation: its possible importance for immunoregulation and as a therapeutic target","volume":"8","author":"Tvedt","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2018.12.006_b0290","unstructured":"Actemra\u00ae [package insert]. South San Francisco, CA, Genentech, 2010."},{"key":"10.1016\/j.humimm.2018.12.006_b0295","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients","volume":"17","author":"Choi","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.humimm.2018.12.006_b0300","unstructured":"Sylvant\u00ae [package insert]. Schaffhausen, Switzerland, Janssen, Biotech 2014."},{"issue":"3","key":"10.1016\/j.humimm.2018.12.006_b0305","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.12266","article-title":"A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma","volume":"161","author":"Voorhees","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.humimm.2018.12.006_b0310","article-title":"Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy","volume":"ID","author":"Meazza","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.humimm.2018.12.006_b0315","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.4049\/jimmunol.173.3.1681","article-title":"Natural, proteolytic release of a soluble form of human IL-15 receptor \u03b1-chain that behaves as a specific, high affinity IL-15 antagonist","volume":"173","author":"Mortier","year":"2004","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.humimm.2018.12.006_b0320","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00007890-199608270-00020","article-title":"Intragraft IL-15 transcripts are increased in human renal allograft rejection","volume":"62","author":"Pavlakis","year":"1996","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.humimm.2018.12.006_b0325","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/art.21249","article-title":"Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study","volume":"52","author":"Baslund","year":"2005","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.humimm.2018.12.006_b0330","first-page":"320","article-title":"Anti-interleukin-12\/23p40 antibody attenuates chronic rejection of cardiac allografts partly via inhibition \u0263-deltaT cells","volume":"169","author":"Wang","year":"2012","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.humimm.2018.12.006_b0335","first-page":"3133","article-title":"A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy","volume":"13","author":"Yuan","year":"2015","journal-title":"J. Exp. Med."},{"issue":"6924","key":"10.1016\/j.humimm.2018.12.006_b0340","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.humimm.2018.12.006_b0345","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs"},{"issue":"9625","key":"10.1016\/j.humimm.2018.12.006_b0350","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"9625","key":"10.1016\/j.humimm.2018.12.006_b0355","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.humimm.2018.12.006_b0360","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.humimm.2018.12.006_b0365","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"9894","key":"10.1016\/j.humimm.2018.12.006_b0370","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.humimm.2018.12.006_b0375","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.humimm.2018.12.006_b0380","first-page":"706","article-title":"Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J. Drugs Dermatol."},{"issue":"8","key":"10.1016\/j.humimm.2018.12.006_b0385","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jama.2011.1211","article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a metaanalysis of randomized controlled trials","volume":"306","author":"Ryan","year":"2011","journal-title":"JAMA"}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019888591830226X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019888591830226X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:50:55Z","timestamp":1759319455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019888591830226X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S019888591830226X"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2018.12.006","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine-targeted therapy for the management of solid organ transplant recipients","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2018.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics.","name":"copyright","label":"Copyright"}]}}